Photocure ASA announced the appointment of BioSyent Pharma Inc. as their exclusive distributor for the commercialization of Cysview in Canada. Under the terms of the agreement, Photocure will receive up to USD 1,000,000 in milestone payments for the rights to Cysview in the territory, which includes USD 650,000 upon signing of the agreement. BioSyent Pharma will fund all costs related to the launch and commercialization of Cysview, which was approved by Health Canada in January 2015.

The market potential in the territory is estimated to be similar to the potential in the Nordics, where Photocure commercializes Hexvix with its own sales team.